Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
22.12
-0.94 (-4.08%)
At close: Feb 21, 2025, 4:00 PM
22.33
+0.21 (0.95%)
After-hours: Feb 21, 2025, 7:33 PM EST
Summit Therapeutics Employees
Summit Therapeutics had 105 employees as of December 31, 2023. The number of employees increased by 28 or 36.36% compared to the previous year.
Employees
105
Change (1Y)
28
Growth (1Y)
36.36%
Revenue / Employee
n/a
Profits / Employee
-$1,873,133
Market Cap
16.31B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 105 | 28 | 36.36% |
Dec 31, 2022 | 77 | -33 | -30.00% |
Dec 31, 2021 | 110 | 29 | 35.80% |
Dec 31, 2020 | 81 | 11 | 15.71% |
Dec 31, 2019 | 70 | 9 | 14.75% |
Dec 31, 2018 | 61 | -15 | -19.74% |
Dec 31, 2017 | 76 | 36 | 90.00% |
Dec 31, 2016 | 40 | 3 | 8.11% |
Dec 31, 2015 | 37 | 14 | 60.87% |
Dec 31, 2014 | 23 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
SMMT News
- 4 days ago - Summit Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results & Operational Progress Call on February 24, 2025 - Business Wire
- 7 days ago - Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - Summit Therapeutics: Data Signals A Potential Paradigm Shift In NSCLC (Rating Upgrade) - Seeking Alpha
- 5 weeks ago - Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025 - Seeking Alpha
- 6 weeks ago - Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
- 7 weeks ago - Best-Performing Stocks Of 2024 - Seeking Alpha
- 2 months ago - Summit Therapeutics Stock Set To Soar By Mid-2025 On HARMONi Phase 3 Trial - Seeking Alpha
- 3 months ago - Summit Therapeutics to Present at Upcoming Investor Conferences - Business Wire